Impact of Prognostic Nutritional Index on Terminal Cancer Patients

Faculty Medicine Year: 2020
Type of Publication: ZU Hosted Pages:
Authors:
Journal: Indian J Palliat Care Wolters Kluwer - Medknow Volume:
Keywords : Impact , Prognostic Nutritional Index , Terminal Cancer Patients    
Abstract:
Background: In terminal cancer patients (TCPs), one of the most important things is to define the survival to help the main responsible physicians, patients, and main caregivers make decisions, set goals, and work across the end‑of‑life strategies. Patients and Methods: We retrospectively reviewed the medical files of TCPs, who died during September 2011 and December 2017, to recognize the correlation between prognostic nutritional indices (PNIs) and survival in those subtypes of patients. The receiver operating characteristic (ROC) curve was used to identify the cutoff value of PNI. Results: A total of 858 TCPs were eligible and included, the median age was 62 years (range: 18–107). The most common primary cancer sites were colorectal cancer in 151 patients (17.6%), hepatobiliary in 129 (15%), lung cancer in 115 (13.4%), breast cancer in 114 (13.3%), and genitourinary in 80 (9.3%). The mean value of PNI for all cancer types was 32.9 ± 6.7. The values showed different levels across cancer types. For patients who lived >2 weeks, PNI was 36.7 compared with that who died within 2 weeks was 29.3, which was a statistically significant (P < 0.001). By the ROC curve, the cutoff value of PNI was 32.3 and area under the curve was 0.888. The sensitivity, specificity, positive predictive value, and negative predictive value were 91.28% (95% confidence interval [CI]: 88.2–93.8), 71.09% (95% CI: 66.5–75.4), 76.5% (95% CI: 73.7–79.2), and 88.8% (95% CI: 85.3–91.5), respectively. Conclusion: The PNI is an easy and an applicable biomarker to estimate life expectancy in TCPs.
   
     
 
       

Author Related Publications

  • Amarallah Abdelmoneim Mohamed Sayed, "Myelodysplastic syndrome from theoretical review to clinical application view", PAGEPress, Italy, 2018 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Patterns of Inpatient Admissions during Haj Clinical conditions, length of stay and patient outcomes at an advanced care centre in Makkah, Saudi Arabia", Pak J Med Sci, 2018 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Neoadjuvant Platinum and Gemcitabine Regimens Precede Definitive Radiotherapy in Locally Advanced Bladder Cancer", Symbiosis, 2019 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Efficacy and Safety of First-Line Pazopanib in Patients with Metastatic Renal Cell Carcinoma: Real-Life Multi Institutional Experience", Remedy Publications LLC, 2019 More
  • Amarallah Abdelmoneim Mohamed Sayed, "?Aggressive Care at the End of Life; Where Are We", Wolters Kluwer - Medknow, 2019 More

Department Related Publications

  • Adel Salah Bakry, "Assessment of Chemotherapy Induced Ovarian Failure Using Serum Anti￾Mullerian Hormone in Premenopausal Breast Cancer Patients", Zagazig University, Faculty of Medicine, 2024 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed", Springer, 2016 More
  • Ola Mohamed Ahmed Elfarargy, ": Prevalence of Androgen Receptors expression in Triple Negative Breast Cancer Patients and its Correlation with Clinicopathological Criteria: Our Institutes experience", abs/10.1200/JCO.2017.35.15_suppl.e1258, 2017 More
  • Rasha Mohamed Mostafa Hagag, "Factors Affecting Survival in Egyptian Patients Suffering from Urinary Bladder Cancer: A Multicenter Retrospective Study", Journal of Cancer Science & Therapy, 2018 More
  • Rasha Mohamed Mostafa Hagag, "Assessment of initial real life experience with Abiraterone Acetate in patients with castrate resistant prostate cancer: A retrospective study in Saudi Arabian patients", International Journal of Advanced Researc h, 2015 More
Tweet